ORGANOGENESIS HOLDINGS Reports Record Earnings Results for FY2023 Q2
August 13, 2023
🌥️Earnings Overview
Organogenesis Holdings ($NASDAQ:ORGO) Inc. released their earning results for Q2 of Fiscal 2023, finishing on June 30th 2023, on August 9th of the same year. Overall revenue was 117.3 million dollars, down 3.4% compared to the same quarter the year before, and net income was 5.3 million, a decrease of 39.1%.
Stock Price
On Wednesday, ORGANOGENESIS HOLDINGS reported their financial results for the second quarter of Fiscal Year 2023. Despite this strong financial performance, ORGANOGENESIS HOLDINGS stock opened at $3.7 and closed at $3.4, representing a drop of 8.4 percent from the prior closing price of $3.7. Analysts attribute the stock decline to a combination of market volatility and uncertainty surrounding the company’s future growth prospects. Despite this pullback in the stock price, ORGANOGENESIS HOLDINGS’ financial results showed solid progress from a year ago and management remains confident in their ability to deliver long-term shareholder value. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Organogenesis Holdings. More…
| Total Revenues | Net Income | Net Margin |
| 457.33 | 10.05 | 2.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Organogenesis Holdings. More…
| Operations | Investing | Financing |
| 16.82 | -36.12 | -4.14 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Organogenesis Holdings. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 450.31 | 179.03 | 2.07 |
Key Ratios Snapshot
Some of the financial key ratios for Organogenesis Holdings are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 19.3% | – | 3.6% |
| FCF Margin | ROE | ROA |
| -4.2% | 3.8% | 2.3% |
Analysis
At GoodWhale, we recently conducted an analysis of ORGANOGENESIS HOLDINGS‘ wellbeing. According to our Risk Rating, ORGANOGENESIS HOLDINGS is a medium risk investment in terms of financial and business aspects. Upon further inspection of their income sheet, balance sheet, and cashflow statement, we detected three risk warnings. If you’d like to know more about our findings, register with us and check it out for yourself. More…
Peers
The company offers a wide range of products and services to its customers. Kerala Ayurveda Ltd, Maywufa Co Ltd, Procyon Corp are some of the leading competitors of Organogenesis Holdings Inc.
– Kerala Ayurveda Ltd ($BSE:530163)
Kerala Ayurveda Ltd is an ayurvedic medicine company that was founded in Kerala, India. The company has a market cap of 808.04M as of 2022 and a Return on Equity of 81.31%. Kerala Ayurveda Ltd manufactures and sells ayurvedic medicines and products. The company’s products are sold in India and exported to other countries.
– Maywufa Co Ltd ($TWSE:1731)
Maywufa Co Ltd is a company that operates in the food and beverage industry. It has a market cap of 2.32B as of 2022 and a ROE of 6.71%. The company is engaged in the production, distribution, and sale of food and beverage products. It offers a wide range of products, including, but not limited to, tea, coffee, juices, and dairy products. The company has a strong presence in China and other Asian countries.
– Procyon Corp ($OTCPK:PCYN)
Procyon Corp is a publicly traded company with a market capitalization of 2.43 million as of 2022. The company has a negative return on equity of 5.43%. Procyon Corp is engaged in the business of providing environmental services. The company offers a variety of services including environmental remediation, waste management, and water treatment.
Summary
ORGANOGENESIS HOLDINGS, a biotechnology company, recently reported their earnings for Q2 2023, with total revenue of USD 117.3 million and net income of USD 5.3 million. This marks a 3.4% and 39.1% decrease in revenue and net income respectively compared to the same period last year. The stock price dropped in response to the news, making it a risky investment in the short term.
However, investors should consider the company’s long-term prospects, such as its research and development initiatives and product pipeline.
Additionally, the company has seen consistent revenue growth in the last few years, suggesting that it may be able to weather current market volatility. Overall, ORGANOGENESIS HOLDINGS could be an attractive investment option for those looking for a long-term growth opportunity.
Related Posts
Recent Posts
